Skip to content

Clinical Application Study of an Improved Dynamic Pre-flushing Method for Hemodialysis Combined with Hemoperfusion

Clinical Application Study of an Improved Dynamic Pre-flushing Method for Hemodialysis Combined with Hemoperfusion

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600121501
Enrollment
Unknown
Registered
2026-03-31
Start date
2026-01-30
Completion date
Unknown
Last updated
2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Renal Failure

Interventions

Experimental Group:1.Slow Flushing Heparinization: Connect the perfusion device to the dialyzer, and attach the arterial end tubing to this pre-flushing system. Start the blood pump and perform the in
Control Group:1.Use normal saline to expel air from the arterial end of the dialysis tubing, then connect the arterial end to the hemoperfusion device, and subsequently connect the hemoperfusion devic

Sponsors

Pangang Group General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Aged between 18 and 80 years, regardless of gender; 2.Diagnosed with end-stage renal disease due to chronic nephritis, diabetic nephropathy, or hypertensive nephropathy, with stable condition, receiving regular hemodialysis (2–3 times per week), and requiring regular HD+HP treatment (HP frequency =2 times per month); 3.Conscious, with good communication skills, able to understand and cooperate with the relevant procedures, examinations, and follow-ups of this study; 4.Voluntarily participating in this study and providing written informed consent signed by the participant or their legal guardian.

Exclusion criteria

Exclusion criteria: 1. Presence of severe cognitive impairment or a history of mental illness (such as schizophrenia or major depressive disorder) that would prevent cooperation with the study; 2. Comorbidities such as active bleeding, severe coagulation dysfunction, or a previous history of allergy to anticoagulants such as heparin; 3. Comorbidities such as malignant tumors, severe heart failure (NYHA Class IV), or severe arrhythmia, with an estimated survival period of less than 6 months or inability to tolerate HD+HP treatment; 4.Participation in other interventional clinical studies during the research period.

Design outcomes

Primary

MeasureTime frame
Coagulation Grading;

Secondary

MeasureTime frame
Treatment Efficiency ;Incidence of acute complications during treatment;

Countries

China

Contacts

Public ContactYuan Hongmei

Pangang Group General Hospital

1617669332@qq.com+86 189 8035 3077

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 17, 2026